NCT04691388 2024-12-05
A Trial of Sintilimab Plus Anlotinib For Metastatic NSCLC After First-Line PD-1 Inhibitor
Zhejiang Cancer Hospital
Phase 2 Completed
Zhejiang Cancer Hospital
Shanghai Zhongshan Hospital
Tang-Du Hospital
Peking Union Medical College Hospital
Tongji Hospital